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Abstract
The objective of this study was to explore the interaction between mouse C2C12
cells and the extracellular matrix, particularly the process of myoblasts converting
to myocytes. This study aimed to create a myogenesis assay that presents a
process to effectively monitor the development of mouse C2C12 myoblasts into
differentiated skeletal myotubes through detection of the protein MyoD.
Myogenesis, the development of muscle tissue, occurs when muscle progenitor
cells, myoblasts, fuse to form multinucleated myotubes, followed by cell fusion
and resulting in a myofiber capable of contraction. An in vitro myogenesis assay
would enable further research to efficiently test the effect of various growth
factors and other parameters on skeletal muscle development, a field with
numerous clinical applications. To test this, cells were seeded on both control
substrates and wells coated with extracellular matrix. Cells were harvested at 3
and 7 days and tested for presence of MyoD. Analysis of PCR results showed
negligible amounts of MyoD present in all experimental wells.
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Introduction
Volumetric muscle loss can be defined as the loss of skeletal muscle resulting in
a reduction or total loss of functionality2. Volumetric muscle loss is a common
injury in the military, as improvised explosive devices have been used
extensively in recent wars. Resulting soft tissue injuries and treatment of
compartment syndrome in the extremities have left many veterans with loss of
muscle functionality14. Volumetric muscle loss is also common in civilian life, as
it can be caused by injuries such as vehicle accidents, gunshot wounds, and
surgical excisions.

The replacement of tissue and promotion of muscle repair following volumetric
muscle loss is a prominent challenge currently being investigated in tissue
engineering. Lack of donor tissue limits the efficacy of procedures using muscle
grafts to replace volumetric muscle loss, and the added challenge of donor-site
morbidity has caused physicians and scientists to turn to tissue engineering as
the most promising alternative to current free muscle transplant procedures10.
Tissue engineering, as a field, seeks to either replace or improve biological
tissues through the combined use of engineered materials, cells, and
biochemical growth factors. Muscle tissue engineering is the branch of tissue
engineering that focuses on the replacement of muscle tissue.

The process of muscular tissue formation is known as myogenesis. In order to
understand adult myogenesis in fully developed skeletal muscle, it is necessary
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to first understand embryonic myogenesis. As the body develops, satellite cells
differentiate into embryonic myoblasts that divide rapidly in the presence of
fibroblast growth factor. Following myoblast proliferation, myoblasts commit to
differentiation, align and join to create myotubes, which are multi-nucleated
fibers. Myotubes then mature into fully mature and functional skeletal muscle
units known as myofibers1. This process is illustrated in Figure 1.

Figure 1. Illustration of myogenesis, the path from a satellite cell to a mature
myofiber15
Various genetic factors are associated with the different stages of myogenesis,
both adult and embryonic. For example, the myogenic regulatory factor family of
basic helix loop helix transcription factors play a large role in the process of
myogenesis, as they both activate the formation of muscle fibers and directly
regulate muscle gene transcription8. MyoD, a protein in the myogenic regulatory
factor family, is necessary for both the initial conversion of a satellite cell to a
skeletal myoblast and for regulation of the myoblast throughout myogenesis.
MyoD self-activates transcription, inducing its characteristic stability in
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commitment to myogenesis and its role in differentiation and repair of injured
skeletal muscle13.

The adult human body is capable of muscle regeneration, but only to a certain
extent3. Necrosis, or death, of muscle cells signals muscle tissue to begin the
process of biological repair and muscle tissue regeneration. Muscle regeneration
is a challenging process, as new muscle must contain vasculature sufficient to
supply the new tissue with oxygen and innervation sufficient for the recovery of
muscle functionality. Skeletal muscle, in comparison to cardiac and smooth
muscle, is capable of a relatively large amount of regeneration due to cells
known as myosatellite cells3.

Myosatellite cells, as with all human skeletal muscle cells, develop embryonically
from the paraxial mesoderm, specifically the somites. Throughout development,
they become part of the dermomyotome7. After the embryonic dermomyotome
differentiation of primary muscle fibers, populations expressing transcription
factors for myosatellite cells exist within the fetal skeletal muscle until a period
late in the development of the fetus, at which time the myosatellite cells are
produced7. The signaling pathway throughout this fetal development of
myosatellite cells is not well understood and is under investigation by several
groups9,12.
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In a fully developed adult, myosatellite cells are quiescent and are found between
the basal lamina and the sarcolemma of the muscle fibers with which they are
associated4. The quiescent state persists until the myosatellites receive an
activation signal indicative of injury to muscle tissue. This signal is transmitted
from the plasma membrane via sphingosine-1-phosphate, a signaling
sphingolipid that incites the myosatellite cell to enter the cell cycle. Mechanical
factors such as stretch can also lead to the activation of myosatellite cells via the
release of myogenesis stimulants such as hepatocyte growth factor or Follistatin,
a molecule that inhibits the negative regulation of myogenesis caused by
Myostatin7. Yet another mode of myosatellite cell activation is that of growth
factors secreted by the microenvironment. Specifically, fibroblast growth factors
have been shown to trigger MAPK signal cascades, which are prerequisite to
myosatellite cell activation5.

Upon activation by muscle injury, myosatellite cells travel to existing muscle
fibers, which they will adhere to in effort to repair damaged fibers and form new
fibers. Activated myosatellite cells proliferate rapidly and differentiate into
myoblasts, at which stage they divide several times prior to forming
multinucleated myofibers7. Due to the terminally differentiated nature of existing
muscle fibers present in adult skeletal muscle, myosatellite cells are solely
responsible for muscle regeneration following injury.
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Volumetric muscle loss describes damage to skeletal muscle that results in the
loss of more tissue than the body is capable of regenerating on its own2. As
muscle tissue engineering seeks to solve this problem through creation of
artificial muscle and promotion of muscle regeneration, it is necessary to further
understand the effects of growth factors and other biochemical substances on
myogenesis. Exclusive use of animal models presents challenges with regard to
both time and cost, which leads to the need for an in vitro assay for use in
preliminary testing.

As stated previously, MyoD is a protein of the myogenic regulatory factor family
that serves as a marker of myoblast commitment to myogenesis13. When
investigating potential tissue engineering methods for promotion of muscle
regeneration, it is possible to use MyoD as a screening tool. An increased
concentration of MyoD indicates greater myoblast commitment to myogenesis,
and thus greater muscle regeneration. This study aimed to profile the expression
of MyoD to create an in vitro myogenesis assay for use in the development of
muscle regeneration therapies.

Methods
In order to test for adequate profiling of MyoD expression in an in vitro assay
while simultaneously investigating the effect of extracellular matrix (ECM) on
C2C12 mouse myoblast cells, six different experimental parameters were tested.
Cells were seeded on a control substrate, a substrate coated with 1 mg ECM per
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mL water, and a substrate coated with 10 mg ECM per mL water to investigate
the effect of the ECM on myoblast differentiation. Cells were collected at 3 and 7
days for each of the substrate conditions. All experimental cells underwent RNA
purification, reverse transcription, and polymerase chain reaction to test for
presence of MyoD.

Muscle harvest
Following the sacrifice of mature Sprague-Dawley rats, all tibialis anterior, bicep
femoris, and gastrocnemius muscles were harvested and rinsed in deionized
water to remove hair and debris. Muscle tissue was then stored in scintillation
vials and frozen at -20°C until enough tissue was harvested to proceed to
decellularization.

Muscle decellularization
All muscle tissues were removed from -20°C and submerged in a room
temperature solution of 1% sodium dodecyl sulfate (Amresco) in 1X pH 7.4
phosphate buffered saline (Life Technologies). The scintillation vials were sealed
and left on a rocking plate. The solution was replaced every 24 hours until the
solution became colorless. The length of this process was approximately 4 days.
Muscle tissues were then submerged in deionized water, which was exchanged
every 6 hours for 24 hours. Muscle tissue was left submerged overnight in a 1X
pH 7.4 phosphate buffered saline solution. The following day, the muscle was
rinsed 3 times in deionized water and left in water overnight. At this point, the
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muscle was completely decellularized and all that remained was the ECM. The
difference in original and decellularized muscle is shown in Figure 2.

Figure 2. Rat bicep femoris before (left) and after (right) decellularization using
1% sodium dodecyl sulfate in 1X phosphate buffered saline solution
Preparation of ECM
ECM was then ground into a fine powder using a mortar and pestle. One piece
of decellularized muscle tissue at a time was placed into the mortar, after which
liquid nitrogen was poured over the tissue. The pestle was then used to powder
the tissue, after which the powder was added to a clean scintillation vial. ECM
powder was stored at 4°C until later use.

Preparation of 12-well plate
To test the effect of ECM on cell growth, 3 different powder concentrations were
used to coat the bottom of two 12-well plates (Greiner Bio-One). 1 mL of pure
deionized water was added to 8 wells, 1 mL of 1mg ECM/mL deionized water
was added to 8 wells, and 1 mL of 10 mg ECM/mL deionized water was added to
8 wells. All water was then allowed to evaporate overnight with the lids of the 12-
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well plate turned slightly askew inside a running biosafety cabinet. Both 12-well
plates were then sterilized using a traditional ethylene oxide sterilization cycle.
Note: an additional 12-well plate with no water or ECM powder was also
prepared and later seeded with cells purely for post-experiment cell density
imaging purposes.

Figure 3. Well of 10 mg ECM powder per mL deionized water, post-evaporation
of 1 mL solution

Preparation of C2C12 cells
C2C12 mouse myoblast cells (ATCC) were used in all cultures. Culture medium
consisted of Gibco Dulbecco’s Modified Eagle Medium (DMEMF12) with 10%
Gibco Fetal Bovine Serum, 1% Gibco GlutaMax L-Glutamine, and 0.1% Gibco
Gentamicin reagent solution. 12 mL of culture media and one thawed vial of
C2C12 cells were added to a T-75 flask (Greiner Bio-One) and incubated at
37°C. Media was replaced every 48 hours until cells reached 75% confluence, at
which point cells were expanded to prevent premature differentiation. At 75%
confluence, cells were passaged and split to two T-175 flasks. The 75%
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confluent cells were treated with 0.25% trypsin-EDTA for detachment. Upon
detachment, cells were removed from T-75 flask and centrifuged 5 minutes at
300G. Following centrifugation, supernatant was removed and 10 mL of new
media was added to the cells. The cell pellet was broken up by pipetting the new
media several times. 5 mL of evenly distributed cell and media mixture was
added to each of the new T-175 flasks. An additional 12 mL of new media was
added to each flask. Cells were allowed to reach 75% confluence, with media
being exchanged every 48 hours.

Seeding Cells
Aiming to seed all C2C12 cells at 30% confluence, a concentration of 14,400
cells/cm2 (55,000 cells/well) was utilized for all wells in 12-well plate. A total of 24
experimental wells and 4 imaging wells were seeded at 30% confluence and
media was added for a total volume of 1 mL/well. Previously described
detachment techniques were used. 55,000 cells/well were also added to 4
additional wells, to be used solely for post-experiment cell density imaging.

Collecting Cells
72 hours after seeding cells, 4 wells of each ECM powder concentration sample
group (0 mg/mL, 1 mg/mL, 10 mg/mL) were collected. After media was removed
from these 12 wells, 200 uL new media and 1 mL RNAprotect cell reagent
(Qiagen) were added to each well and incubated at 37°C for 15 minutes.
Following incubation, cells were fully detached. The contents of each of the 12
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wells were transferred to a separate labeled 1.5 mL microcentrifuge tube
(Qiagen) and stored at -80°C. Media was removed from 2 of the 4 wells seeded
for imaging and 1 mL 4% paraformaldehyde (Sigma) was applied for 15 minutes
to fix the cells. Paraformaldehyde was removed and the cells were left
submerged in 1X pH 7.4 phosphate buffered saline at 4°C, where they were left
until imaging. Used media was removed and 1mL new media was applied to the
12 experimental and 2 imaging wells that were not either fixed or detached.

7 days after the seeding of cells, the remaining 4 wells of each ECM powder
concentration sample group were collected. After media was removed from
these 12 wells, 200 uL new media and 1 mL RNAprotect cell reagent (Qiagen)
were added to each well and incubated at 37°C for 15 minutes. Following
incubation, cells were fully detached. The contents of each of the 12 wells was
transferred to a separate labeled 1.5 mL microcentrifuge tube (Qiagen) and
stored at -80°C. Media was removed from the remaining 2 wells seeded for
imaging and and 1 mL 4% paraformaldehyde (Sigma) was applied for 15 minutes
to fix the cells. Paraformaldehyde was removed and the cells were left
submerged in 1X pH 7.4 phosphate buffered saline at 4°C until imaging.

Cell density imaging
The 4 wells fixed for imaging were removed from 4°C and placed at room
temperature. Phosphate buffered saline was removed. 700 uL DAPI nucleic
acid stain was added to each well and left for 10 minutes. DAPI was then
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removed and wells were rinsed 3 times with 1X pH 7.4 phosphate buffered
saline. Wells were then imaged at 100X.

RNA purification and reverse transcription
All RNA purification was performed using the RNeasy Protect Cell Mini Kit from
Qiagen. Following immediate stabilization of nucleic acids in experimental
C2C12 cells using RNAprotect cell reagent as described above in the ‘collecting
cells’ section, total RNA purification was performed. Stabilized experimental cells
were removed from storage at -80°C and allowed to thaw in a water bath at
37°C. After thawing, the cells were centrifuged. The cell pellet was lysed and
homogenized using a guanidine-thiocyanate buffer, thus inactivating RNAses to
protect all existing RNA. The homogenized lysate was placed in a gDNA
Eliminator spin column, which used in conjunction with a salt buffer resulted in
removal of all genomic DNA. Ethanol was then added to RNA flow-through to
allow RNA to bind, after which an RNeasy spin column was used to isolate RNA
and eliminate all contaminants. RNA was then eluted in RNAse-free water.
Reverse transcription of isolated RNA was then performed using the iScript
cDNA Synthesis Kit (Bio-Rad).

Polymerase Chain Reaction
All polymerase chain reaction (PCR) procedures were carried out using MyoD1
primer (Bio-Rad) as a gene of interest, GAPDH primer (Bio-Rad) as a
housekeeping gene, and SYBR Green (Bio-Rad) as a DNA-binding dye.
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Results
Cell density imaging results are shown in Figure 4. There was a drastic increase
in confluence of mouse C2C12 cells from 3 days to 7 days. Cells were initially
seeded at 30% confluence, and imaged with DAPI for nucleic acid staining. All
images were taken at 100X magnification.

Figure 4. Mouse C2C12 cells at 3 (left) and 7 (right) days following seeding at
30% confluence, imaged with DAPI for nucleic acid staining at 100X
magnification
Analysis of PCR results showed negligible amounts of MyoD present in all
experimental wells. The housekeeping gene, GAPDH, presented at 2000-2500
relative fluorescent units (RFU). PCR results showed there was no MyoD present
in 11 of the 12 tested wells. The one well that contained MyoD presented at 1200
RFU.

Conclusion
Results from PCR showed a lack of MyoD in 11 of 12 experimental wells. The
presence of GAPDH, the housekeeping gene, shows that there was indeed
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enough genetic material collected and purified to glean results with PCR. The
absence of MyoD could possibly be due to presence of Myf5 instead, a similar
gene with functional redundancy6. The absence of MyoD also could indicate that
the mouse C2C12 cells did not reach the confluence during the 3 to 7 days of
incubation that was required for further differentiation and thus expression of
MyoD.

Results showing no MyoD in any experimental wells present the possibility that
the model used in this experiment was ineffective. Sources of error leading to an
ineffective assay include but are not limited to media formulation and cell density.
In a similar experiment by Kong et al., C2C12 myoblasts were treated with
chloroquine and DNA calcium phosphate precipitates prior to plating in order to
promote stable DNA transfections6. Cells were also switched to a differentiation
medium consisting of low-glucose DMEM and 2% horse serum prior to
differentiation6. Kong et al. used a similar seeding density to this experiment,
differing by less than 1,000 cells/cm2, and allowed cultures a maximum of four
days before harvest.

Several operational shortcomings also arose throughout the experiment,
including but not limited to RNA purification and PCR techniques. Due to the
inherent instability of RNA, storage at -80°C for several days prior to RNA
purification could have affected the amount of RNA that was intact and available
for isolation. During RNA isolation, trace amounts of phenol could have
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remained in the RNA, thus introducing error into RNA quantification.
Degradation of the DNA template from nucleases in the testing environment or
contaminants present in the master mix could have contributed to downstream
error in PCR.

Failure to detect MyoD effectively using this assay leads to a search for other
methods of monitoring myogenesis. In future work, another method of screening
for myogenesis using an in vitro system could be utilization of imaging devices to
monitor myoblast differentiation. As myoblasts proliferate and differentiate, they
align into a network of parallel, multinucleated myotubes7. Through
characterization of the surface topography of experimental wells, it is possible to
quantify the degree of alignment and thus the degree of differentiation of
myoblasts into myotubes.

Future experimentation using RNA purification and PCR would call for further
investigation into media formulations and protocols to promote myogenesis and
appropriate cell culture length. Significant presence of MyoD in similar studies
was only noted after the use of specific differentiation mediums6. In future work,
there is also need for additional practice in RNA isolation and PCR techniques in
order to reduce the likelihood of DNA degradation, contamination, and pipette
error.
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